Actemra™ Shows Impressive, Consistent Remission Rates

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics
Article Date: 16 Nov 2006 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:3 stars

3 (1 votes)


Three Japanese randomized clinical trials evaluating tocilizumab monotherapy revealed consistent response of tocilizumab in RA patients. Remission rates exceeded 50% at 52 weeks and one study showed 43.3% achievement of ACR70. (Abstract #945).

The authors concluded that "targeted blockade of IL-6 signaling is a viable approach to the treatment of RA".

American College of Rheumatology Annual Congress (ACR)

http://www.mabthera-ra.com

Article adapted by Medical News Today from original press release.
Visit our arthritis / rheumatology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Ian Fergusson. "Actemra™ Shows Impressive, Consistent Remission Rates." Medical News Today. MediLexicon, Intl., 16 Nov. 2006. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/56791.php>

APA
Ian Fergusson. (2006, November 16). "Actemra™ Shows Impressive, Consistent Remission Rates." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/56791.php.

Please note: If no author information is provided, the source is cited instead.




Arthritis / Rheumatology

What is Rheumatoid Arthritis?

Rheumatoid arthritis, sometimes referred to as rheumatoid disease, is a chronic (long lasting), progressive and disabling autoimmune disease that causes inflammation (swelling) and pain in the joints, the tissue around the joints, and other organs in... Read more...

Most Popular Articles





Follow Our Arthritis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Arthritis / Rheumatology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »